Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019 : A Population-Based, Serial Cross-Sectional Analysis
© 2024 Menzies-Gow et al..
Purpose: Associations between systemic glucocorticoid (SGC) exposure and risk for adverse outcomes have spurred a move toward steroid-sparing treatment strategies. Real-world changes in SGC exposure over time, after the introduction of steroid-sparing treatment strategies, reveal areas of successful risk mitigation as well as unmet needs.
Patients and Methods: A population-based ecological study was performed from the Optimum Patient Care Research Database to describe SGC prescribing trends of steroid-sparing treatment strategies in primary care practices before and after licensure of biologics in the United Kingdom from 1990 to 2019. Each analysis year included patients aged ≥5 years who were registered for ≥1 year with a participating primary care practice. The primary analysis was SGC exposure, defined as total cumulative SGC dose per patient per year, for asthma, severe asthma, chronic obstructive pulmonary disease (COPD), nasal polyps, Crohn's disease, rheumatoid arthritis, ulcerative colitis, and systemic lupus erythematosus. Secondary outcomes were percentages of patients prescribed SGCs and number of SGC prescriptions per patient per year.
Results: The number of patients who met study inclusion criteria ranged from 219,862 (1990) to 1,261,550 (2019). At the population level, patients with asthma or COPD accounted for 67.7% to 73.2% of patients per year with an SGC prescription. Over three decades, decreases in SGC total yearly dose ≥1000 mg have been achieved in multiple conditions. Patients with COPD prescribed SGCs increased from 5.8% (1990) to 34.8% (2017). SGC prescribing trends for severe asthma, Crohn's disease, and ulcerative colitis show decreased prescribing trends after the introduction of biologics.
Conclusion: Decreases in total yearly SGC doses have been shown in multiple conditions; however, for conditions such as severe asthma and COPD, an unmet need remains for increased awareness of SGC burden and the adoption or development of SGC-sparing alternatives to reduce overuse.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Pragmatic and observational research - 15(2024) vom: 26., Seite 53-64 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Menzies-Gow, Andrew N [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biological products |
|---|
| Anmerkungen: |
Date Revised 21.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/POR.S442959 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369953444 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369953444 | ||
| 003 | DE-627 | ||
| 005 | 20240322001056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240320s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/POR.S442959 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1339.xml |
| 035 | |a (DE-627)NLM369953444 | ||
| 035 | |a (NLM)38505738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Menzies-Gow, Andrew N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019 |b A Population-Based, Serial Cross-Sectional Analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 Menzies-Gow et al. | ||
| 520 | |a Purpose: Associations between systemic glucocorticoid (SGC) exposure and risk for adverse outcomes have spurred a move toward steroid-sparing treatment strategies. Real-world changes in SGC exposure over time, after the introduction of steroid-sparing treatment strategies, reveal areas of successful risk mitigation as well as unmet needs | ||
| 520 | |a Patients and Methods: A population-based ecological study was performed from the Optimum Patient Care Research Database to describe SGC prescribing trends of steroid-sparing treatment strategies in primary care practices before and after licensure of biologics in the United Kingdom from 1990 to 2019. Each analysis year included patients aged ≥5 years who were registered for ≥1 year with a participating primary care practice. The primary analysis was SGC exposure, defined as total cumulative SGC dose per patient per year, for asthma, severe asthma, chronic obstructive pulmonary disease (COPD), nasal polyps, Crohn's disease, rheumatoid arthritis, ulcerative colitis, and systemic lupus erythematosus. Secondary outcomes were percentages of patients prescribed SGCs and number of SGC prescriptions per patient per year | ||
| 520 | |a Results: The number of patients who met study inclusion criteria ranged from 219,862 (1990) to 1,261,550 (2019). At the population level, patients with asthma or COPD accounted for 67.7% to 73.2% of patients per year with an SGC prescription. Over three decades, decreases in SGC total yearly dose ≥1000 mg have been achieved in multiple conditions. Patients with COPD prescribed SGCs increased from 5.8% (1990) to 34.8% (2017). SGC prescribing trends for severe asthma, Crohn's disease, and ulcerative colitis show decreased prescribing trends after the introduction of biologics | ||
| 520 | |a Conclusion: Decreases in total yearly SGC doses have been shown in multiple conditions; however, for conditions such as severe asthma and COPD, an unmet need remains for increased awareness of SGC burden and the adoption or development of SGC-sparing alternatives to reduce overuse | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biological products | |
| 650 | 4 | |a drug prescriptions | |
| 650 | 4 | |a drug utilization | |
| 650 | 4 | |a glucocorticoids | |
| 650 | 4 | |a practice patterns | |
| 700 | 1 | |a Tran, Trung N |e verfasserin |4 aut | |
| 700 | 1 | |a Stanley, Brooklyn |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Victoria Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Smolen, Josef S |e verfasserin |4 aut | |
| 700 | 1 | |a Bourdin, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzgerald, J Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Raine, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Chapaneri, Jatin |e verfasserin |4 aut | |
| 700 | 1 | |a Emmanuel, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Price, David B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pragmatic and observational research |d 2010 |g 15(2024) vom: 26., Seite 53-64 |w (DE-627)NLM265586518 |x 1179-7266 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g day:26 |g pages:53-64 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/POR.S442959 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |b 26 |h 53-64 | ||